Across TCGA pan-cancer cohorts, NXNL1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NXNL1 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NXNL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NXNL1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
BLCA and SKCM are the cancer types where NXNL1 Mutation most reproducibly stratifies survival.